Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALVISTA PHARMACEUTICALS, INC.

(KALV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Number of employees : 70 people.
Sales per Business
20202021Delta
Pharmaceuticals12.69100%---
USD in Million
Sales per region
20202021Delta
United States12.69100%---
USD in Million
Managers
Name Title Age Since
T. Andrew Crockett Chief Executive Officer & Director 45 2016
Benjamin L. Palleiko Chief Financial & Business Officer 54 2019
Edward P. Feener, Dr. Chief Scientific Officer 60 2016
Paul K. Audhya, Dr. Chief Medical Officer - 2021
Albert Cha Independent Director 47 2016
Edward W. Unkart Independent Director 70 2016
Brian Jude Gerard Pereira, Dr. Independent Director 61 2019
Daniel B. Soland Independent Director 62 2019
Nancy Stuart Independent Director 61 2021
Leah Monteiro Senior Director-Communications & IR - 2016
Members of the board
Name Title Age Since
Martin W. Edwards, Dr. Chairman 64 2019
T. Andrew Crockett Chief Executive Officer & Director 45 2016
Albert Cha Independent Director 47 2016
Edward W. Unkart Independent Director 70 2016
Brian Jude Gerard Pereira, Dr. Independent Director 61 2019
Daniel B. Soland Independent Director 62 2019
Nancy Stuart Independent Director 61 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 24,436,492 22,881,497 93.6% 0 0.0% 93.6%
Shareholders
NameEquities%
Deerfield Management Company LP 1,806,037 7.39%
Franklin Advisers, Inc. 1,487,700 6.09%
RA Capital Management LP 1,399,489 5.73%
Eventide Asset Management LLC 1,373,000 5.62%
SSgA Funds Management, Inc. 1,077,992 4.41%
Merck & Co., Inc. 1,070,589 4.38%
BlackRock Fund Advisors 1,061,531 4.35%
Polar Capital LLP 1,011,055 4.14%
The Vanguard Group, Inc. 958,367 3.92%
Longwood Fund Management LLC 934,484 3.83%
Company contact information
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway
Suite 901 East
Cambridge, MA 02142

Phone : +1.857.999.0075
Fax : +1.866.553.3269
Web : http://www.kalvista.com